United States - English - NLM (National Library of Medicine)

fosun pharma usa inc. - ziprasidone mesylate (unii: 3x6sax83jz) (ziprasidone - unii:6uka5vej6x) - ziprasidone mesylate for injection, intramuscular is indicated for acute agitation in schizophrenic patients. when deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone’s greater capacity to prolong the qt/qtc interval compared to several other antipsychotic drugs [see warnings and precautions (5.3)]. prolongation of the qtc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and  sudden death. in many cases this would lead to the conclusion that other drugs should be tried first. whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [see warnings and precautions (5.3)] acute treatment of agitation in schizophrenia - ziprasidone mesylate for injection intramuscular is ind

United States - English - NLM (National Library of Medicine)

fosun pharma usa inc. - ziprasidone mesylate (unii: 3x6sax83jz) (ziprasidone - unii:6uka5vej6x) - ziprasidone mesylate for injection, intramuscular is indicated for acute agitation in schizophrenic patients. when deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone’s greater capacity to prolong the qt/qtc interval compared to several other antipsychotic drugs [see warnings and precautions (5.3)]. prolongation of the qtc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and  sudden death. in many cases this would lead to the conclusion that other drugs should be tried first. whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [see warnings and precautions (5.3)] acute treatment of agitation in schizophrenia - ziprasidone mesylate for injection intramuscular is ind

United States - English - NLM (National Library of Medicine)

dr.reddy's laboratories, inc. - ziprasidone mesylate (unii: 3x6sax83jz) (ziprasidone - unii:6uka5vej6x) - ziprasidone mesylate for injection intramuscular is indicated for acute agitation in schizophrenic patients. when deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone’s greater capacity to prolong the qt/qtc interval compared to several other antipsychotic drugs [see warnings and precautions (5.3)]. prolongation of the qtc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and  sudden death. in many cases this would lead to the conclusion that other drugs should be tried first. whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [see warnings and precautions (5.3)] acute treatment of agitation in schizophrenia - ziprasidone mesylate for injection intramuscular is indicated for the treatment of acute agitation in schizophrenic adult patients for whom

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - dolasetron mesylate -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - dolasetron mesilate monohydrate -

United States - English - NLM (National Library of Medicine)

gland pharma limited - ziprasidone mesylate (unii: 3x6sax83jz) (ziprasidone - unii:6uka5vej6x) - ziprasidone mesylate for injection intramuscular is indicated for acute agitation in schizophrenic patients. when deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone’s greater capacity to prolong the qt/qtc interval compared to several other antipsychotic drugs [see warnings and precautions (5.3)]. prolongation of the qtc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and  sudden death. in many cases this would lead to the conclusion that other drugs should be tried first. whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [see warnings and precautions (5.3)] acute treatment of agitation in schizophrenia - ziprasidone mesylate for injection intramuscular is indicated for the treatment of acute agitation in schizophrenic adult patients for whom

United States - English - NLM (National Library of Medicine)

novadoz pharmaceuticals llc - ziprasidone mesylate (unii: 3x6sax83jz) (ziprasidone - unii:6uka5vej6x) - ziprasidone mesylate for injection intramuscular is indicated for acute agitation in schizophrenic patients. when deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone’s greater capacity to prolong the qt/qtc interval compared to several other antipsychotic drugs [seewarnings and precautions (5.3)]. prolongation of the qtc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. in many cases this would lead to the conclusion that other drugs should be tried first. whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [see warnings and precautions (5.3)]  acute treatment of agitation in schizophrenia -    ziprasidone mesylate for injection intramuscular is indicated for the treatment of acute agitation in schizophrenic adult patients for whom tre

United States - English - NLM (National Library of Medicine)

roerig - ziprasidone mesylate (unii: 3x6sax83jz) (ziprasidone - unii:6uka5vej6x) - ziprasidone 20 mg in 1 ml - geodon intramuscular is indicated for acute agitation in schizophrenic patients. when deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone's greater capacity to prolong the qt/qtc interval compared to several other antipsychotic drugs [see warnings and precautions (5.3)] . prolongation of the qtc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. in many cases this would lead to the conclusion that other drugs should be tried first. whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [see warnings and precautions (5.3)] . acute treatment of agitation in schizophrenia - geodon intramuscular is indicated for the treatment of acute agitation in schizophrenic adult patients for whom treatment with ziprasidone is appropriate and who need intram

United States - English - NLM (National Library of Medicine)

tya pharmaceuticals - ziprasidone mesylate (unii: 3x6sax83jz) (ziprasidone - unii:6uka5vej6x) - ziprasidone 20 mg in 1 ml - geodon is indicated for the treatment of schizophrenia, as monotherapy for the acute treatment of bipolar manic or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder. geodon intramuscular is indicated for acute agitation in schizophrenic patients. when deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone's greater capacity to prolong the qt/qtc interval compared to several other an tipsychotic drugs [ )]. prolongation of the qtc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. in many cases this would lead to the conclusion that other drugs should be tried first. whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [ ] see

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - dolasetron mesylate -